Compass Pathways' COMP360 Phase 3 Data Bolsters Regulatory Path for TRD Treatment
Event summary
- Compass Pathways announced positive top-line results for its Phase 3 COMP006 trial evaluating COMP360 (psilocybin) for treatment-resistant depression (TRD).
- The trial’s primary endpoint, change in MADRS scores at Week 6, showed a statistically significant reduction (-3.8 points, p<0.001) with a 25mg dose compared to a 1mg control.
- Combined data from COMP005 and COMP006 suggest durable treatment effects lasting at least 26 weeks with a single or two doses of 25mg COMP360.
- Compass plans to submit a rolling NDA to the FDA in Q4 2026, following a meeting to discuss the submission process.
The big picture
Compass Pathways’ consistent Phase 3 results represent a significant advancement in the treatment of TRD, a market with limited therapeutic options and a substantial unmet need. The company’s focus on psilocybin-based therapies positions it at the forefront of a nascent wave of psychedelic-assisted treatments, but regulatory and reimbursement hurdles remain substantial. Success hinges on demonstrating a compelling value proposition to both clinicians and payers.
What we're watching
- Regulatory Risk
- The FDA’s receptiveness to Compass’s proposed rolling NDA submission and potential for accelerated approval will be a key determinant of commercial launch timelines.
- Durability Data
- The 26-week data from COMP006, expected in early Q3 2026, will be critical in validating the long-term efficacy and potential for reduced retreatment frequency.
- Market Adoption
- The willingness of payers to reimburse COMP360, given its novel mechanism of action and potential for high cost, will significantly impact market penetration within the TRD patient population.
Related topics